<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T15:54:19Z</responseDate>
  <request identifier="oai:figshare.com:article/34025695" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34025695</identifier>
        <datestamp>2026-09-29T17:24:44Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_811</setSpec>
        <setSpec>category_61</setSpec>
        <setSpec>category_62</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Correlation between ks-cfDNA and urine creatinine.&lt;/p&gt;</dc:title>
          <dc:creator>Vanessa C. Heron (25138198)</dc:creator>
          <dc:creator>John B. Whitlam (22153063)</dc:creator>
          <dc:creator>David H. Murray (733029)</dc:creator>
          <dc:creator>Nicky Boulter (3485630)</dc:creator>
          <dc:creator>Peter Mount (4424851)</dc:creator>
          <dc:creator>Suet-Wan Choy (335780)</dc:creator>
          <dc:creator>Marina Katerelos (5782778)</dc:creator>
          <dc:creator>Kathy Paizis (5782793)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Mathematical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Developmental Biology</dc:subject>
          <dc:subject>Marine Biology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>np participants (&lt;</dc:subject>
          <dc:subject>np controls (&lt;</dc:subject>
          <dc:subject>exploratory study found</dc:subject>
          <dc:subject>centre prospective case</dc:subject>
          <dc:subject>1 – 15</dc:subject>
          <dc:subject>et quantities normalised</dc:subject>
          <dc:subject>normotensive pregnant controls</dc:subject>
          <dc:subject>20 np controls</dc:subject>
          <dc:subject>specific epigenetic targets</dc:subject>
          <dc:subject>quantify three kidney</dc:subject>
          <dc:subject>urine creatinine demonstrated</dc:subject>
          <dc:subject>3 – 5</dc:subject>
          <dc:subject>urinary creatinine levels</dc:subject>
          <dc:subject>versus 62 copies</dc:subject>
          <dc:subject>represented total cfdna</dc:subject>
          <dc:subject>cfdna showed non</dc:subject>
          <dc:subject>et ): ks</dc:subject>
          <dc:subject>59 – 0</dc:subject>
          <dc:subject>cfdna quantities reflect</dc:subject>
          <dc:subject>xlink "&gt; cell</dc:subject>
          <dc:subject>rptec marker ).</dc:subject>
          <dc:subject>cfdna markers ks</dc:subject>
          <dc:subject>preeclampsia &lt;/ p</dc:subject>
          <dc:subject>urinary creatinine</dc:subject>
          <dc:subject>absolute quantities</dc:subject>
          <dc:subject>specific cell</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>versus 3</dc:subject>
          <dc:subject>podocyte marker</dc:subject>
          <dc:subject>normotensive pregnancies</dc:subject>
          <dc:subject>including urine</dc:subject>
          <dc:subject>20 women</dc:subject>
          <dc:subject>urinary kidney</dc:subject>
          <dc:subject>81 copies</dc:subject>
          <dc:subject>231 copies</dc:subject>
          <dc:subject>quantifying kidney</dc:subject>
          <dc:subject>p &lt;/</dc:subject>
          <dc:subject>kidney injury</dc:subject>
          <dc:subject>cell death</dc:subject>
          <dc:subject>047 ).</dc:subject>
          <dc:subject>028 ).</dc:subject>
          <dc:subject>005 ).</dc:subject>
          <dc:subject>significant increases</dc:subject>
          <dc:subject>predictive ability</dc:subject>
          <dc:subject>organ injury</dc:subject>
          <dc:description>&lt;p&gt;Scatter plots showing relationships between urinary kidney-specific epigenetic targets (ks-et) and urine creatinine. (a-c) Each ks-et plotted against urine creatinine. A linear regression line is shown to illustrate the trend. (d) Urine creatinine versus total cell-free DNA (t-cfDNA), with t-cfDNA values plotted on a log&lt;sub&gt;10&lt;/sub&gt;-scaled y-axis. (e-g) Fractional ks-et (%ks-et) plotted against urine creatinine. A linear regression line illustrates trend. Spearman’s correlation coefficient (ρ) and corresponding &lt;i&gt;P&lt;/i&gt; values are shown for each plot. Each point represents an individual sample.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-29T17:24:37Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pone.0359105.g003</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Correlation_between_ks-cfDNA_and_urine_creatinine_p_/34025695</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
